The invention relates to a method offeeding liquid enteral nutritional products and particularly to modifying a liquid enteral nutritional product having a viscosity in the range of from 1 to about 300 centipoises (cps.) by adding ingredients during the feeding thereof into the gastrointestinal tract of a patient.
BACKGROUND OF THE INVENTION
The feeding of a liquid enteral nutritional product from a hangable container, such as a bottle or a plastic bag with a bottom outlet connecting to a drip chamber and the latter to a flexible tubing, or lumen, leading to a nasogastric tube or a feeding tube inserted through a gastrostomy or a jejunos tomy, by gravity flow or aided by a pump, is well known.
The liquid enteral nutritional product may be aseptically processed or terminally retorted, and may be supplied in a pre-filled, ready-to-hang container, or placed in such a container by a caregiver. However, the selection of diets, particularly special diets, from amongst the rather modest number of typically available liquid enteral nutritional prod ucts is limited. This narrows, as a practical matter, the choices of the attending physician as to diet modifications, temporary or long term, that might significantly benefit the patient. In view of the now-recognized importance of pro viding aseptic nutritional compositions, it can be seen that modified diets are not easily prepared without observing the stringent requirements needed to deliver an aseptic nutri tional composition to the patient. The need to observe such requirements has heretofore militated against preparing small quantities of special diets designed for a specific patient.
Moreover, a number of nutrients as well as medicaments, diagnostic agents, and other ingredients such as probiotics, that at any given time might be desirable to orally administer to a patient are not stable during heat sterilization or may not be mutually compatible with other desired ingredients for an extended period of time, such as days or even months until used, and thus are not readily amenable to large scale preparation and consequent storage as the product moves through commerce.
Drug delivery systems have been described and claimed in U.S. Pat. Nos. 4, 511, 353, 5, 318, 558 and 5, 324, 280 in which the drug component to be delivered is stored in a capsule from which it is ejected over time upon osmotic infusion of moisture into the capsule, the drug being carried away from the outside surface of the capsule by a suitable liquid in an intravenous, i.e., parenteral, delivery system, or even, by the device of U.S. Pat. No. 5,318,558, by body fluids upon implantation of the capsule.
In U.S. Pat. No. 5,069,671 there is described a formula tion chamber, which may also be a drip chamber, in which various forms of sustained release mechanisms are employed to release a drug or medicament, or other physi ologically beneficial component such as a nutrient, within the formulation chamber from which the drug or other component is carried by a suitable liquid into a parenteral delivery system. The teachings of U.S. Pat. Nos. 4, 511, 353 and 5, 069, 671 are directed to intravenous delivery of parenteral composi tions, and in the case of the latter patent, includes delivery by infusion through intravenous, intraarterial, intraperito neal or subcutaneous routes. The osmotic dosage system of U.S. Pat. No. 5, 324, 280 is concerned with the delivery of drug formulations over time to a biological environment, such as a tissue or organ implant in a mammal, or a stream or tank for marine life. The osmotically driven device of U.S. Pat. No. 5, 318 ,558 is said to be usable to deliver drugs, medicaments and nutrients in a range of environments extending from veterinary medicine to human drug admin istrations, and to hobby situations such as fish tanks. Again, in the case of human administration, the delivery appears to be within a tissue or organ implant.
Although the osmotic delivery devices and other forms of sustained or controlled release dosage forms or reservoirs have been known for some time, so far as is known, there has been no attempt to utilize such a delivery system to add one or more nutrients, or one or more medicaments, or a mixture of nutrients and medicaments, or a probiotic, or a diagnostic agent, or any of these in admixture with a marker dye, to a liquid enteral nutritional product, with a viscosity up to 300 cps., during the administration of the nutritional product to the gastrointestinal tract of a patient. Liquid enteral nutri tional products currently on the market are described in the reference text "Nutrition In Critical Care', Gary P. Zaloga, ed., Mosby-Year Book Inc., St. Louis, Mo., 1994, at Chapter 24, authored by Barbara Hopkins, Part III, "Feed ing ', pp. 439-467 . This reference indicates that complete nutrient compositions contain proteins, carbohydrates, fibers, fats, and vitamins and minerals in various proportions in an aqueous or aqueous/fat medium. Nutrient composi tions for special diets may omit one or more classes of these components.
SUMMARY OF THE INVENTION
A first aspect of the invention concerns an apparatus for adding ingredients to a liquid enteral nutritional product during delivery of the nutritional product from a supply thereof, such as a hangable container, to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient.
The apparatus comprises: a formulation chamber, usually in the form of a drip chamber, connectable to a supply container of a liquid enteral nutritional product, normally an aqueous com position, the formulation chamber having an inlet and an outlet, at least one beneficial agent in controlled release dosage form, each controlled release dosage form unit being disposed in the formulation chamber so as to be wetted by or immersed in the liquid enteral nutritional product traversing the formulation chamber, and each beneficial agent being dispersible in the medium of the liquid enteral nutritional product, and fluid communication means connecting the outlet of the formulation chamber to a tube for feeding the modified enteral nutritional product, containing the so-added at least one beneficial agent, into the gastrointestinal tract of a patient. Each at least one beneficial agent that is to be added in controlled release dosage form during feeding is added in at least a physiologically effective or diagnostically detectable amount and is selected from the group consisting of: a nutritional ingredient; a medicament ingredient; a chemi cally and physiologically compatible mixture of: a plurality of nutritional ingredients, or a plurality of medicament 5,531,734 3 ingredients, or at least one nutritional ingredient and at least one medicament ingredient; a probiotic; or a diagnostic agent; and, any of the foregoing ingredients or mixtures of ingredients in admixture with at least one physiologically acceptable, and ingredient compatible, marker dye or dye mixture that is dispersible in the medium of the liquid enteral nutritional product.
The formulation chamber may be a conventional drip chamber which here serves also as the formulation or contact chamber. The formulation chamber may be pro vided, in addition to the controlled release dosage form or forms therein, and whether or not marker dye is employed, with the same or different beneficial agent or agents not in controlled release dosage form, if desired, in order to add greater amounts of such, or to add a beneficial agent as a bolus. Further, the marker dye or dyes may be provided separately from the beneficial agents, in the formulation chamber, in one or more controlled release dosage forms.
If desired, one or more additional contact or formulation chambers may be employed, either in series or in parallel, but feeding into one fluid communication means leading to the feeding tube of a patient. Wherein more than one formulation chamber is used, at least one formulation cham ber will have positioned therein at least one controlled release dosage form containing at least a useful or detectable amount of at least one beneficial agent as above defined, while each additional formulation chamber may contain one or more beneficial agents in either or both controlled release and non-controlled release dosage forms. The use of more than one formulation chamber facilitates the addition of ingredients not readily available in combination or not compatible during storage together in a controlled release dosage form. In each formulation chamber the beneficial agent or agents, whether in controlled release dosage form or not, are positioned, and held or supported, if necessary, so that the liquid enteral nutritional product being modified contacts and wets or immerses the dosage form of the beneficial agent or agents therein. Preferably, each controlled release dosage form is shaped or held in such a manner as to prevent or avoid the beneficial agent blocking flow of the liquid enteral nutritional product out of the drip chamber or formulation chamber in which it is positioned.
The combination of (1) a formulation chamber, ordinarily in the form of a drip chamber, and (2) fluid communication means, accompanied by (3) at least one beneficial agent, as herein defined, in controlled release dosage form disposed in the formulation chamber, or, merely accompanying the formulation chamber, in either case when the three parts are supplied together, constitutes a useful kit for evacuating a liquid enteral nutritional product from a supply container, such as a hangable container, and modifying the liquid enteral nutritional product by adding one or more beneficial agents thereto as it is flowing from the container and feeding the modified product into the gastrointestinal tract of a patient. The formulation chamber of the kit may also be loaded with or be accompanied by a marker dye or dyes in a separate controlled release dosage form and/or one or more beneficial agents in a suitable non-controlled dosage release form, for example, in uncoated particulate or tablet form in a porous carrier envelope such as a tea bag-like packet. The marker dye or dyes may be of types visible under either or both white light or ultraviolet light. Preferably, the at least one beneficial agent in controlled release dosage form and any other additives in non-controlled release dosage forms supplied as part of a kit are already positioned in the formulation, or drip, chamber. If not, they are readily 4 manually placed in the formulation chamber, ordinarily prior to connecting the apparatus to the supply container from which the liquid enteral nutritional product is to be evacu ated.
In a further aspect of the invention, the invention concerns a method of preparing a special liquid diet for enterally feeding a tube fed patient comprising modifying a liquid enteral nutritional product during the flow thereof from a supply container containing such composition to a feeding tube leading into the gastrointestinal tract of the patient. More specifically, the method comprises the steps of:
A. providing an apparatus comprising: (a) a formulation chamber having an inlet and an outlet, the inlet being connected in fluid communication to the supply container of the liquid enteral nutritional prod uct, (b) a physiologically effective or diagnostically detectable amount of at least one beneficial agent in controlled release dosage form, each beneficial agent being dis posed in the formulation chamber so that the dosage form thereof is contacted by or immersed in the liquid enteral nutritional product traversing therethrough, each beneficial agent being dispersible in the medium of the liquid enteral nutritional product and each ben eficial agent in controlled release dosage form being selected from the group consisting of a nutritional ingredient; a medicament ingredient; a chemically and physiologically compatible combination of: a plurality of nutritional ingredients, or a plurality of medicament ingredients, or at least one nutritional ingredient and at least one medicament ingredient; or a probiotic ingre dient; or a diagnostic agent; and, any of the foregoing ingredients or combinations of ingredients together with at least one compatible, physiologically accept able, marker dye that is dispersible in the medium of the liquid enteral nutritional product, and (c) fluid communication means capable of operatively connecting the outlet of the formulation chamber to a tube for feeding a liquid enteral nutritional product into the gastrointestinal tract of the patient; B. providing a supply container containing a liquid enteral nutritional product; C. placing the apparatus in communicative series in the fluid flow between the supply container and the feeding tube; and, D. flowing the liquid enteral nutritional product through the apparatus wherein the product becomes modified and into the feeding tube.
In a modification of this method which may be especially useful in tailor-making a diet for a patient, one or more beneficial agents that are not in controlled release dosage form are added to the formulation chamber. The added beneficial agent or agents may be the same or different than the specific beneficial agent or agents provided in the formulation chamber in controlled release dosage form. The added beneficial agents which are not in controlled dosage form are added to accomplish abolus feeding or bolus effect, or, simply to add a greater amount of a given beneficial agent. Also, marker dye in a separate controlled release dosage form, which may be surface coated with readily soluble dye to impart quick initial dye marking, may be added to the formulation chamber. In another modification the fluid communication means is provided with one or more additional formulation, or contact, chambers, that are not necessarily drip chambers, but which each have positionedtherein either a marker dye, or, a beneficial agent, as herein defined, in controlled or non-controlled release form, or a 5,531,734 5 combination of marker dye and beneficial agent. The for mulation chambers are connected to a supply of liquid enteral nutritional product and positioned so as to permit the flow of the liquid enteral nutritional product over each dosage form therein to contact it or even immerse it dynami cally, i.e., immerse it in a quantity of liquid that constantly turns over, in order to take up the beneficial agent and/or dye content and convey such to a feeding tube of a patient. A pump may be used, if needed or desired, to flow or help flow the modified liquid enteral nutritional product into the feeding device or tube.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be better understood with reference to the appended drawings in which:
FIG. 1 is a partly schematic representation of an apparatus for modification of a liquid enteral nutritional product and tube feeding it nasogastrically according to the invention; inserted through the closure and depending therefrom and with a beneficial agent in controlled release dosage form disposed inside the drip chamber and immersed in the flowing liquid enteral nutritional product, the lower part of the drip chamber and the controlled release dosage form within being partly broken away and in section, and the tubing portion of the fluid communicating means, i.e., primarily the tubing leading away from the drip chamber, being truncated for purposes of illustration;
FIG. 5 is a perspective view of a drip chamber usable according to the invention with a controlled release dosage form in the shape of a substantially rectangular solid with slightly rounded corners disposed within the drip chamber, the beveled inlet tube end of the drip chamber being the upper end that is thrust in the normal manner through the closure of the supply container to communicate therewith and receive liquid enteral nutritional product therefrom;
FIG and used in a formulation chamber in addition to one or more controlled release dosage form units or separately if there is at least one such controlled release dosage form placed in the same formulation chamber or in at least one formulation chamber used with the same communication means. A small quantity of marker dye not in controlled release dosage form may also be placed in the fibrous packet for quick initial dye marking;
FIG. 10 is a view in side elevation and partly truncated, of a feeding set, or kit, including a beneficial agent in controlled release dosage form to be placed in the formu lation chamber by the caregiver, the kit being useful in modifying a liquid enteral nutritional composition during the feeding thereof according to the invention; . 20 is a view in side elevation of part of the apparatus for modifying a liquid enteral nutritional product during enteral feeding wherein two formulation chambers are sus pended from respective hanging supply containers, each containing liquid enteral nutritional product, the outlets of the formulation chambers being connected to tubing seg ments that connect to a "Y" fitting that joins the parallel flow from each formulation chamber into a single stream within the communication means, here truncated.
DEFINITIONS USED HEREN
The following terms and phrases are defined for the purposes of the description and claims.
"Enteral' nutritional products refers to liquid composi tions commonly understood to be supplied to and utilized in the gastrointestinal tracts of patients. Such enteral nutritional products have a viscosity in the range of 1 to about 300 cps. and most frequently in the range of about 5 to about 150 cps.
"Enteral nutritional product medium" refers to the liquid portion of a liquid enteral nutritional product, mainly water, but often including lesser or minor amounts of one or more liquid non-aqueous substances such as lipids, e.g., vegetable oil and marine oil.
The term "gastrointestinal tract' as used herein refers only to the stomach and the small bowel. Feeding to the gas trointestinal tract is done by use of a nasogastric tube extending through a nasal passage and the esophagus and thence to the stomach, or by use of a feeding tube extending through the abdominal wall to the stomach or small intes tine.
A "physiologically significant' or "beneficial" ingredient is an ingredient that is, or is believed to be, nutritionally or pharmaceutically important to the patient, or is otherwise medically important as in the case of a probiotic, or, a diagnostic agent such as an opaquing agent.
A "probiotic" is understood to be a live microbial food supplement which beneficially affects the human host by improving the individual's microbial balance in the gas trointestinal tract, e.g., Lactobacillus reuteri.
A "beneficial agent or ingredient that is dispersible in the medium of the liquid enteral nutritional product' is an agent or ingredient that is physiologically beneficially added, or otherwise usefully beneficially added, as in the case of a diagnostic agent, to the liquid nutritional product during enteral feeding, and is dispersible in the medium of the nutritional product. The beneficial agent(s) or ingredient(s), whether or not supplied by, i.e., from, controlled release dosage form units or devices, and used according to the invention, must be dispersible in the medium of the liquid enteral nutritional product being modified during feeding, in order to be carried along with the nutritional product into the gastrointestinal tract of the patient.
A "useful amount' of a beneficial ingredient that is dispersible in the medium of the liquid enteral nutritional product is an amount that is "physiologically effective or diagnostically detectable' with respect to a patient, i.e., it produces, or is reasonably expected to produce, a detectable beneficial effect on the patient on either a short term or long term basis when fed as part of a liquid enteral nutritional product, or, is detectable in diagnosing a condition or disease. Generally not more than about 5 grams of beneficial agent will be contained in a single controlled release dosage form unit or device, and a plurality or even multiplicity of units such as microencapsulated microspheres containing a given beneficial agent may be employed to provide a desired level of the beneficial agent in the nutritional product being fed.
The phrase "at least one beneficial agent dispersible in the medium of the liquid enteral nutritional product' is meant to refer to the singular as well as the plural, as may well be adjudged from the context, and includes combinations of ingredients, agents or factors.
The term "dispersible' as used herein with respect to beneficial agent(s) or ingredient(s) is to be understood to apply to substances that are soluble as well as those that are suspendable enough to be taken up readily and carried along by the liquid medium as the liquid enteral nutritional product flows through the formulation chamber containing the one or more controlled release dosage forms.
The term "feeding set' refers to the combination of a drip chamber, or other formulation chamber, and fluid commu nication means leading to a feeding tube for enteral feeding. The drip chamber or other formulation chamber is loaded with or accompanied by at least a useful amount of at least one beneficial agent in controlled release dosage form, the beneficial agent being as above defined with or without a marker dye in combination and with or without additional beneficial agent that is not in controlled release dosage form, The term also encompasses such a feeding set having at least one additional drip chamber or one or more formulation chambers in fluid flow series or in parallel, as a part of the fluid communication means, each feeding set having at least one drip chamber or formulation chamber loaded with at least one beneficial agent in controlled release dosage form, each beneficial agent being present in at least a useful amount as above defined. Where more than one formulation chamber is employed, the additional chamber or chambers may contain: (1) one or more beneficial agents in controlled release dosage form only, with or without marker dye in controlled release dosage form; or (2) one or more beneficial agents in controlled release dosage form intermingled with one or more beneficial agents not in controlled release dosage form, and with or without marker dye in controlled release dosage form; or (3) one or more beneficial agents none of which are in controlled release dosage form, and with or without marker dye in controlled release dosage form.
The process of "infusion' is meant to refer, in the present context, to the process of supplying an enteral-soluble beneficial ingredient to the gastrointestinal tract of a patient extending over time from at least a minute to about 30 hours, but more usually at least about 2 hours to about 24 hours.
The term "delivery means' denotes generically a means or system for storing and subsequently delivering or releas 5,531,734 ing a beneficial ingredient or agent or mixture thereof within a formulation chamber such as a drip chamber during, and as a consequence of, the flow therethrough of a liquid enteral nutritional product utilizing a controlled release dosage form of the beneficial ingredient or agent.
The term "a controlled release dosage form" refers to any of the well known conventional controlled release forms, such as a coated tablet, osmotic delivery device, coated capsule, microencapsulated particles such as microspheres, agglomerated particles, e.g., molecular sieve particles, or a fine, hollow, permeable-walled fiber as a bundle of chopped fibers or a coil, each a form that contains and stores and subsequently releases, or disperses in the case of the osmoti cally driven devices, a useful content of a beneficial agent into the medium of a liquid enteral nutritional product at room temperature in a slow, or delayed or intermittent manner as compared to the solubility characteristics nor mally exhibited by that beneficial agent, when in uncoated or untreated particulate form, in the said medium at about room temperature. Any dosage form which employs coating, encapsulation, microencapsulation, enclosure in an osmoti cally driven device, or capture in a molecular sieving type structure or in a permeable fine hollow fiber, to retard or slow down, delay or intermittently delay solubilization of a promptly Soluble beneficial agent so that its dissolution, or disperson as with an osmotically driven device, takes place during the course of at least 30 minutes, and preferably at least two hours, of contact by flowing liquid enteral nutri tional product, or, the release is delayed, i.e., not com menced, for at least 10 minutes after initial contact in a formulation chamber by the liquid enteral nutritional prod uct, is exhibiting controlled release behavior. As to a ben eficial agent that is inherently not promptly soluble in the medium of a liquid enteral nutritional product, any such dosage forms that retard or slow down, delay or intermit tently delay solubilization of such a beneficial agent by at least 20 percent of the normal time for solubilization or dispersion into the medium of a liquid enteral nutritional product, of a given unit amount of the beneficial agent that is not coated or treated to obtain a controlled release is considered for the purposes of the description and claims to be a controlled release dosage form. Preferably, the con trolled release dosage forms prolong release of the contents thereof for a time appropriate to the nutrient or medicament or other beneficial agent being supplied. On the other hand, merely tableting a beneficial agent either unmixed with another material, or not admixed with a relatively insoluble binder type excipient, for example, while resulting in a smaller surface area being exposed to a solvent liquid and a slower dissolution rate than that of a fine particulate form of the beneficial agent, is not to be consid ered making the beneficial agent into a controlled release dosage form. Clearly, a beneficial agent in a particulate form that has not been coated with or enclosed in any other material is not in controlled release dosage form. Nor are uncoated tablets or particles of a beneficial agent, clearly not in controlled release dosage form, to be considered trans formed into controlled release form merely by being enclosed in a carrier such as a fibrous tea bag type of packet or an easily dissolved or disintegrated capsule. here The "controlled release dosage forms' useful according to the invention are understood to include delayed or intermit tent release as well as sustained release dosage forms, some of which constitute "rate controlling means' or "rate con trolled dosage forms'. Any dosage form that delivers, over a period of at least 30 minutes or with a delay of at least 10 minutes, a beneficial agent into the liquid enteral nutritional 10 product flowing through a formulation chamber having the dosage form therein, is considered to be a controlled release dosage form for the purposes of the invention. Preferably, the controlled release dosage forms prolong release of the contents thereof for a time appropriate to the nutrient or medicament being supplied.
The terms "controlled release dosage form units' or "controlled release dosage form particles' are to be under stood to refer to individual coated tablets or coated capsules or devices such as osmotic delivery devices or microcapsule particles or small bundles of fine hollow fibers or small agglomerated clumps of molecular sieving type material, each capable of the sustained delivery or delayed or inter mittent delivery of beneficial agent or dye as defined above.
It should also be understood that the phrase "flowing the liquid enteral nutritional product through the apparatus, wherein it becomes modified, and into the feeding tube' is meant to include utilizing gravity flow from a hanging container, as well as using a pump in addition to or without gravity flow to promote the flow of the modified liquid enteral nutritional product into and through a feeding tube. It may be helpful to utilize two formulation chambers in tandem, such as drip chambers 27 and 73 as seen in FIG. 19 , to introduce a greater concentration or amount of a given ingredient. The formulation chambers may be used in tan dem also to introduce different respective beneficial ingre dients that are not supplied together within the same con trolled release dosage form unit or particle. The respective ingredients may constitute a little-used combination, for example, or they may not be compatible in storage together within a controlled release reservoir.
Two formulation chambers are shown in use sequentially in series in the feeding set of FIG. 16 wherein the second formulation chamber 76 is attached at the end of the flexible tubing 54 which is distal from the supply container. This may be found useful for adding a special beneficial ingre dient to a feeding set already made up. With the formulation 5,531,734 11 chamber 76 at the end of the set which is distal from the supply container, it will most likely be positioned horizon tally as depicted, and is preferably made with a bulbous mid-portion 77 or a low lying longitudinal channel portion wherein the beneficial agent 32 in controlled release dosage form will lie at the lower side of the formulation chamber and be wetted by the flowing liquid enteral nutritional product. If the beneficial agent is not in controlled dosage formit will likewise lie, for example, at the lower side of the bulbous section 77 until dispersed.
Dual formulation chambers 74 may be used in parallel as indicated in FIG. 20 , and for the same reason as the tandem chambers, or, it may be simpler wherein it is desired to feed one beneficial agent on a bolus basis and another on a sustained basis. It is preferable to hang such chambers from respective supply containers, as shown, to avoid problems of control in order to get adequate flow through both formu lation chambers from a single supply container, which would preferably require the use of a splitter valve to apportion intake flow between the two parallel routes. The Referring again to FIG. 1, the formulation chamber 27 has positioned therein a controlled release dosage form unit 32 containing at least a physiologically effective or diagnosti cally detectable amount of at least one beneficial ingredient that is dispersible in the medium of the liquid enteral nutritional product 33 flowing from the supply container 22 into the formulation chamber 27 where the liquid enteral nutritional product, which is normally water-based, contacts the controlled release dosage form unit 32, wetting it or immersing it within the formulation chamber 27, causing the release or discharge into the nutritional composition of the dispersible beneficial ingredient or ingredients, in addition to marker dye if included, stored in the reservoir. The flow of liquid enteral nutritional product is conveniently started or shut off or sometimes regulated by the use of a conven tional adjustable compression clip 34.
Turning now to FIG. 2 , a hanging supply container 22 is shown supplying liquid enteral nutritional product 33 to a formulation chamber 27 from which the liquid enteral nutritional product flows through flexible tubing 54 of the feeding set 20a to the gastrostomy feeding tube 23a. The gastrostomy feeding tube shown in FIG. 3 is merely exem plary of the large variety of gastrostomy feeding tubes which are commercially available, it being understood that the apparatus of the present invention is usable with a variety of gastrostomy feeding tubes.
In FIG. 3 there is shown a feeding arrangement for a jejunostomy much like the apparatus in FIG. 1 , except that the feeding set 20b is adapted to be used with a pump 35 which provides positive flow into a feeding tube 23b leading to the small bowel 26a of the patient, whereas in a number of cases gravity flow is utilized. Also, a second formulation chamber 27a is employed as part of the feeding set 20b in order to add additional or different beneficial agent and/or marker dye, each dispersible in the medium of the liquid enteral nutritional product 33 flowing from the supply container 22 to formulation chamber 27 and thence through the rest of the communication means 28b and formulation chamber 27a of feeding set 20b to the jejunostomy feeding tube 23b. The additional beneficial agent may be in con trolled or non-controlled dosage form.
If desired, or needed, as often is the case when feeding via a feeding tube, such as a jejunostomy tube, a pump, such as No. 4,927,411, and connected in series in the communica tion means, may be used to flow or help flow the modified liquid enteral nutritional product into the feeding tube, for example, when it is not convenient to hang or otherwise locate the supply container in an elevated position relative to the patient, or, when the nutritional product is rather viscous and flows slowly by gravity flow. The fluid communication means 28 of the apparatus utilized will ordinarily include a flexible tubing portion 54 connectable to or usable with a conventional pump. If the pump employed, for example, is a peristaltic pump that requires especially shaped flexible tubing, such tubing may be substituted for all or apart of the communication means delivering modified nutritional prod uct from the formulation chamber to the feeding tube of the patient.
The end of the flexible tubing 54 connected to the inlet end of second formulation chamber 27a is preferably pro vided with a coupling element 30 such as that shown in the feeding set in FIG. 15 , while the inlet end of the formulation chamber is shaped complementarily to receive the coupling element, and the outlet of the formulation chamber commu nicates with a short length of flexible tubing which likewise terminates in a coupling element 30, that is connected to the feeding tube 23b. It may be seen that it is convenient to add the second formulation chamber 27a, when the need arises, without having to disconnect the parts of the feeding set.
Here, for example, the flexible tubing 54 would have to be disconnected from the drip chamber 27 to add the formu lation chamber 27a directly in tandem at that end of the set.
The formulation chamber 27 has been loaded with a beneficial agent in controlled release dosage form 32, while the second formulation chamber 27a has been provided with the same or a different beneficial agent not in controlled release dosage form. The use of beneficial agent not in controlled release dosage form is illustrated also in FIG. 14 where a plurality of sustained release dosage form units 32 containing beneficial agent(s) are supported above the pierced plate 53 along with beneficial agent not in controlled release dosage form as particles or dispersible tablets 80.
The formulation chamber 27a may be hung vertically, like a conventional drip chamber, but will probably be more conveniently positioned with the direction of flow of the liquid enteral nutritional product therethrough approxi mately horizontal. Consequently, the formulation chamber 27a should be provided with means to guide or channel the liquidnutritional product to physically contact the controlled release dosage form unit or units therein. Such means may be a low lying longitudinal channel in the body wall or a bulbous enlargement of the chamber body of the sort illus trated in FIG.16 or even a simple lateral depression in the sidewall of the lower side of the chamber, or, a trap, or weir, or any other means to retain the dosage form units where there will be an adequate flow or depth of liquid sufficient to afford good contact with the controlled release dosage form units or particles located in such guide or channel means. As seen in FIG. 16 , a feeding kit has been provided with a second formulation chamber 76 with a bulbous body portion 77 in which a controlled release dosage form unit 32 is positioned so that flow of liquid enteral nutritional product will steadily contact the controlled release dosage form unit 32 and take up beneficial agent therefrom.
In the enlarged fragmentary view in FIG. 4 , a controlled release dosage form unit 32a in the form of an osmotic 5,531,734 13 device capsule is seen immersed in a liquid enteral nutri tional composition33 within the drip chamber 27. This kind of controlled release dosage form unit 32a, which has an outer coating or membrane that does not disintegrate readily, should have, preferably, a geometric shape, for example, that of a rectangular solid, that will avoid blocking flow of liquid enteral nutritional product 33 through a circular opening such as that of the channel 40 serving as the outlet of the lower part 39 of the drip chamber 27, or, other means such as a mesh sleeve may be employed to prevent such blockage.
The details of construction of one example of a conven tional drip chamber suitable for use as a formulation cham ber according to the invention are illustrated in FIGS. 5 and 6 which are greatly enlarged perspective views. The drip chamber 27 as shown has two parts. The first part is a hollow, nearly cylindrical chamber body 37 with an open first end 38, which is the upper end when the drip chamber is in its normal operative position, and a second end 39, opposite the first end, that tapers or narrows down to form an orifice 40 leading to an integrally formed outlet tube portion 29. The chamber body 37 is preferably formed of a clear material, such as plastic or glass, to allow see-through visibility of the flow of the nutritional product. Usually the drip chamber is formed of a clear, somewhat flexible, autoclaveable plastic, such as a clear polyvinylchloride or polyolefin resin. The second part of the drip chamber 27 shown is in the nature of a plug 42 with a cylindrical body that has an inward end portion 43 that snugly press fits into the inlet end 38 of the chamber body 37. Preferably the end portion 43 of the plug body 37 that extends into the chamber body has a slightly reduced diameter. The edge 44, of this end portion 43, remote from the end face of the plug is raised slightly, being a little larger in diameter, and serves as stop when assembling the chamber body and the plug together. The plug body is provided with an integrally formed fluid communication passage 45 which may take the form of an axial borehole in a solid plug body that communicates with an inlet tube portion 46 that projects outwardly in the axial direction from a collar-like flange 47 that extents radially from the top end 48 of the plug body. But, preferably, in order to provide a plug body with more resiliency for easier insertion into the upper end 38 of the chamber body 37, the fluid communication passage 45 is a concentric tube axially located within and about as long as the plug body. The concentric tube 45 is integrally formed with or otherwise operatively connected to the inlet tube portion 46. A short, peripheral, integrally formed flange 50 that extends longi tudinally from the collar-like flange 47 along a side of the plug body may be provided, if desired, to aid in gripping the plug body when assembling the drip chamber.
The plug may be molded of a plastic such as a polyvi nylchloride resin, which may be pigmented, if desired, for visibility as an aid to observe proper seating in the chamber The drip chamber shown in FIGS. 5 and 6 has a controlled release dosage form unit 32 disposed therein ready for use. The controlled release dosage form unit will be preselected according to the contents thereof to provide the additional nutrient(s) and/or medicament(s) and/or probiotic(s) and/or diagnostic agent(s) and/or other beneficial ingredient(s) selected by the care giver in charge, along with a marker dye, if desired. As used herein and in the claims, medicaments are understood to be substances used in therapy. The formula tion chamber, or chambers, selected may contain more than one controlled release reservoir in order to provide a com bination of nutrients, or, a combination, such as nutrients and medicaments or other beneficial agents, tailored to the needs of the patient being fed. The formulation chamber may also be one provided with the same or different beneficial agent or agents both in controlled and not-controlled release dosage form in order to provide, for example, a greater amount, as in the case of a nutrient. A non-controlled dosage form of a beneficial agent may be used to supply the beneficial agent over a shorter period of time, as might be desired with a medicament.
The controlled release dosage form units employed will preferably be in the form of a coated tablet, an osmotic delivery device, a coated capsule, a microencapsulated microsphere, an agglomerated particle, e.g., as of molecular sieving type particles, or, a fine hollow permeable fiber bundle, or chopped hollow permeable fibers, agglomerated or held in a fibrous packet. To avoid having a dosage form unit or particle block the flow of the liquid enteral nutritional composition through the outlet orifice 40 of the drip cham ber, if the dosage form unit is one that maintains integrity of the exterior layer or coating thereof while the ingredients leach out or are expressed out during contact with the liquid enteral nutritional product, it is preferred that the dosage form unit have a geometric shape, e.g., a rectangular Solid, or a star shape, either of which will not fully block around passageway. If a different type of controlled release dosage form is used which dissolves or disintegrates so the interim shape is not controllable, or if it leaves an insoluble skeletal structure or debris, it is preferred to confine the controlled release dosage form units in a mesh-like bag within the drip chamber or other formulation chamber such as the mesh sleeve 51 shown in FIG. 11 . In FIG. 11 there is also shown a plurality of controlled release dosage form units which may be employed in order to provide additional beneficial ingredients that are dispersible in the medium of the liquid enteral nutritional product in order to obtain a tailor-made nutrient composition for the patient. This may be especially helpful wherein none of the controlled release dosage forms at hand may have the exact combination of ingredients that is desired or needed for a patient, and the combination can be made up a la carte if there are at hand controlled release dosage form units containing the various ingredient contents desired.
As seen is FIG. 12, a foraminous sleeve, or bag, that is, one with numerous holes in it, may be used to position the controlled release reservoir(s) in the drip chamber or other formulation chamber.
Or, turning now to FIG. 13 , a plastic or ceramic or corrosion resistant metal plate 53 that is foraminous or 5,531,734 15 pierced may be placed within the body of the lower part of the drip chamber 37, or other formulation chamber, to support the controlled release dosage form units, in this case, a very large number where the desired ingredient is needed in relatively large amount. If desired, the foraminous plate 53 may be replaced by a grid or screen 41, such as that shown in FIG. 13A and is also preferably formed of a plastic or vitrified ceramic or corrosion resistant metal, such as stainless steel.
The foregoing means of disposing, i.e., supporting, the controlled release dosage form units within the drip chamber may also be used in any additional formulation chambers in the feeding set employed.
The controlled release dosage form unit depicted in FIG.  7 is of the osmotic pump type that functions in the manner of the osmotically driven delivery device described and claimed in U.S. Pat. No. 5,318,558, the specification and drawings of which are incorporated herein by reference with respect to the structure of the controlled release dosage form units therein described and the method of making them and their mode of functioning, albeit here with different envi ronments and contents and end uses. In the pump type controlled release dosage form units, or delivery devices, the beneficial ingredient(s) in liquid form, i.e., either in the liquid state or in solution in a suitable solvent, is expressed out from a cylindrical enclosure or cavity 56 within the reservoir through a small orifice 57 by the action of a piston 58 driven by pressure developed by osmotic infusion of moisture through a semi-permeable membrane 59 confining a hydro-active substance 60 behind the piston 58, driving the piston steadily toward the side of the reservoir where the ingredient(s) 61 is forced out through the orifice 57. Orifice 57 is very small and is preferably drilled by a laser beam. The cylindrical enclosure 56 is formed within an outer non-permeable membrane or coating 62. The hydro-active substance 60 may be a water-soluble salt like magnesium sulfate, magnesium chloride, potassium sulfate, sodium chloride, sorbitol, inositol, urea, or a saccharide such as glucose or fructose or dextran, or, a hydrophilic polymer such as a poly(hydroxyalkyl methacrylate) with a molecular weight of 30,000 to 5,000,000, or a poly(vinylpyrrolidone) with a molecular weight of 10,000 to 360,000, an anionic or cationic hydrogel or polyvinyl alcohol having low acetate residual.
The controlled release reservoir depicted in FIG. 8 is another osmotic dosage system with a sustained release dosage form that functions in the manner of the osmotically operated delivery device described and claimed in U.S. Pat. No. 5,324,280, the specification and drawings of which are hereby incorporated herein by reference with respect to the structure of the sustained release dosage form units there described and the method of making them and their mode of functioning, albeit here with different environments and contents and end uses. In this type of system, the beneficial ingredient(s) 63 to be fed in liquid state or solution form, is enclosed within a non-permeable coating 64 that is sur rounded by a layer 65 of hydro-active material that is entirely confined within an outer semi-permeable membrane coating 66. Osmotic pressure developing in the hydro-active layer 65 upon infusion of moisture thereinto compresses the core 67 containing the liquid form beneficial ingredient(s) 63 and forces that liquid out steadily through a very small passageway 68 from the core 67 to the exterior of the may be a coating of marker dye or beneficial agent for the purpose of getting a quick initial release of such dye or beneficial agent. In the case of a beneficial agent such as a medicament, this may be desirable in order to get a blood content level up quickly, after which a steady sustained release level may be needed.
The controlled release reservoir 70 depicted in FIG. 9 is of the type in which there is provided, within a carrier envelope 71 that is very quickly soluble or disintegrable in the medium of the liquid enteral nutritional product, a quantity of microcapsules or molecular sieving type par ticles 72. If microcapsules, the particles 72 are microspheres each individually coated and each containing the same beneficial ingredient or mixture thereof, with a plurality of distinct numerical portions or fractions thereof each pro vided with a coating that dissolves or disintegrates in or is permeated by the medium of the liquid enteral nutritional product. The various numerical fractions, respectively, each have a coating of a different thickness whereby upon making a blend of the microcapsules with a fraction that is uncoated, the mixture shows a sustained release effect when exposed to an aqueous medium, such as the medium of a liquid enteral nutritional product. The envelope and coatings must essentially be acceptable for nutritional feeding, or disinte grable, i.e., suspendable, but not necessarily soluble.
If the particles 72 are of a molecular sieving type, or a mixture of two or more molecular sieving grades, the particles have been impregnated with a beneficial ingredient or ingredients to be supplied during feeding and the particles agglomerated into desired size granules or clumps that are usable, with or without being coated, to form a controlled release dosage form usable according to the invention, the coating, if applied, being soluble, or disintegrable, i.e., suspendable, in or permeable to the medium of the liquid enteral nutritional product to be modified. The molecular sieving type material has a porous structure with non aligned pores where pore size is critically controlled in manufacture in order to create the property of holding molecules of different size characteristics or molecular weights in a selective manner. The holding or storing properties impart sustained release behavior.
The carrier for controlled release dosage form units may also take the form shown in FIG. 9 but containing a fibrous material in which the fibers are hollow and permeable and slowly release substances such as the beneficial ingredients herein added to a nutritional product. A measured quantity of such fibers, in a coil or in chopped form, may be used in a retaining means such as a sleeve or bag, or agglomerated with a binder, or coated with a dispersible, disintegrable or permeable coating. Such fibers, which may be formed primarily of a cellulose ether or ester, are capable of storing up and subsequently yielding up a beneficial ingredient or mixture of ingredients, upon contact with flowing liquid enteral nutritional product within the drip chamber or other The fibrous and highly porous tea bag-type of carrier envelope 79 shown in FIG. 9A may also be used to hold or support, within a formulation chamber, a quantity of microencapsulated microspheres, or a quantity of molecular sieving type material or, for example, a quantity of chopped fine hollow permeable fibers 78, any of which forms holding or containing a dosage amount of one or more beneficial agents. Such a tea bag-type of envelope, or a plurality thereof, may also be used to position within a formulation chamber any combination of: (1) one or more beneficial agents in controlled release dosage form; (2) one or more beneficial agents in controlled dosage form along with one or more beneficial agents not in controlled dosage form, wherein the beneficial agents not in controlled dosage form may be the same or different agents than those present in controlled dosage form; and (3) a marker dye or dye mixture in combination with either (1) or (2) and in a controlled release dosage form setting, as well as in any external coatings of controlled release dosage form units. Wherein more than one formulation chamber is used, the additional formulation chamber may have positioned therein, e.g., a fibrous carrier bag having therein only non-controlled ben eficial agent along with or without marker dye.
Any mode of making a sustained or controlled release storage coating, envelope or binder may be used in making a controlled release dosage form unit usable according to the invention so long as the soluble, dispersible or disintegrable components of the dosage form units used are physiologi cally acceptable and the controlled release dosage form unit is capable of storing one or more beneficial ingredients as above defined until use and releasing the same into a liquid enteral nutritional product at a useful rate or manner and/or over a useful period of time of at least one-half hour and preferably over at least two hours during enteral feeding, or longer if needed for certain medicaments and nutrients. Tablets and capsules and other dosage forms may generally be coated with well known materials that slow down and delay the solubilization or suspension of the beneficial agent, materials such as Zein, shellac, methacrylate polymers and copolymers, and cellulose ethers and esters that are frequently used for the purpose. Such materials are described in U.S. Pat. No. 5,160,742 and are generally adaptable for the present purpose, although the coated articles described in the patent are used in a different manner.
Wherein it is necessary or quite important to provide a beneficial ingredient, or a mixture of ingredients, as herein defined, for example, one or more medicaments, according to the invention and at a fairly uniform rate over time, with preferably not more than about a 25% variation above or below the median rate over a period of two to about 24 hours or more, the osmotic pump and other osmotic delivery systems are to be preferred. Generally, a wide range of rates is usable as long as at least an effective amount is supplied without reaching excessive amounts.
Amongst the beneficial agents that are most likely to be added to conventional enteral nutritional compositions are, for example, nutrients, such as, glutamine, arginine, vita mins, fermentable dietary fibers, non-fermentable dietary fibers, enzymes such as lipases, combinations of amino acids, oligosaccharides such as fructo-oligosaccharides, short chain (C-C) fatty acids, pyruvate precursors in the form of pyruvamide, or pyruvyl-amino acids, such as, pyru wyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-va line, pyruvyl-sarcosamine and their amides, esters and salts, structured lipids, d-Chiroinositol, lactoferrin, marine oils and acidulents such as ascorbic acid. An example of a structured lipid which provides excellent nutritional support is a glycerol backbone with at least one gamma linolenic acid or dihomogamma-linolenic acid residue in combination with a medium chain (C-C) fatty acid residue and a C-C m-3 fatty acid residue selected from alpha-linolenic and stearodonic, eicosapentaenoic and docosahexaenoic If desired, a physiologically acceptable marker dye or dye mixture may be provided in the formulation chamber or chambers in addition to one or more of the beneficial ingredients above disclosed in order that the flow of modi fied liquid nutritional product may be made visible as an aid to the caregiver. This may be done by placing in the formulation chamber one or more sustained release dosage form units containing both the dye or dye mixture and the beneficial ingredient(s), if such dosage form units are avail able. Or, a controlled release dosage form unit containing the dye or dye mixture and a separate controlled release dosage form unit containing the beneficial ingredient(s) may be placed together in the formulation chamber. As indicated above, in order to impart prompt visibility to the flow of modified nutritional product as an aid to the caregiver, it may be preferred to apply an external, readily soluble coating of the marker dye to a controlled release dosage form unit, ordinarily one containing marker dye. The marker dye is admixed with a small amount of one or more conventional easily dispersible tablet coating excipients, such as, polyvi nylpyrrolidone having an average molecular weight in the range of about 35,000 to 50,000, mannitol, magnesium stearate, and Zein or guar gum, in applying the dye to the dosage form unit during manufacture. Generally the amount of excipients in total is less than about 10 percent by weight of the coating. Or, the dosage form unit may be simply dipped in a solution of the marker dye and dried.
A marker dye or dye mixture that is useful according to the invention is a colorant dye or a fluorescent dye or a mixture of such dyes that is physiologically acceptable to the patient and compatible with the beneficial agents being fed therewith. The dye or dye mixture must also be capable of being taken up in detectable concentration in the liquid medium of the liquid enteral nutritional product while the product flows through a drip chamber or other formulation chamber having positioned therein at least one sustained release dosage form unit containing the marker dye or dyes. If the dye is detectable in the drip chamber, it can be expected to be detectable, ordinarily, if it somehow reaches the oral cavity of the patient.
The marker dye employed may be a colorant dye that imparts color that is visible under white light, for example, normal daylight or artificial room light encountered in a hospital or clinic, or, the marker dye may be a fluorescing dye that fluoresces visibly under ultraviolet light, or, a mixture of a colorant dye and a fluorescing dye. A mixture of a colorant dye and a fluorescing dye appears to be especially advantageous in that flow through the formulation chamber is readily perceived under normal lighting condi tions with colorant dye present, while even a small amount of nutritional product out of place, for example, in the oral cavity or nasal passage, will be more easily detected with the aid of ultraviolet light if it contains a fluorescing dye. This is because of the nature of the fluorescing dyes that are especially visible under ultraviolet light even when present in very low concentration.
The dye or dye mixture used must be physiologically acceptable. Usually food grade colorant dyes approved under the provisions of the United States Food, Drug and Cosmetic Act are suitable. Preferred are F.D. & C. Blue #1 and F.D. & C. Blue #2 dyes. The dye or dye mixture used must be soluble in the medium of the liquid enteral nutri tional product being fed and compatible with the beneficial ingredient(s) being added during the feeding. Generally about 0.1 milligram of dye per milliliter of liquid enteral nutritional product is desired to give a readily visible col oration to the nutritional product.
Wherein it is important to be able to detect misdirected liquid enteral nutritional product, the marker dye used may be a fluorescing dye, such as F.D.& C. Red #3, which is highly visible at a very low concentration under ultraviolet light and also imparts a visible coloration to the liquid nutritional product under white light conditions. Other suit able fluorescing dyes are: quinine, F.D.& C. Red #22, F.D.& C. #28, fluorescein, and D 282 UV Blue available from DaGlo of Cincinnati, Ohio and also identified as 16470-24-9 in the Chemical abstracts System with a color index of 220. as a fluorescent brightener. As indicated above, if desired, a mixture of colorant dye and fluorescing dye may be used. Generally, adding to the nutritional product in the formula tion chamber about 0.01 to 0.05 mg/ml of fluorescing dye is adequate for detectability under ultraviolet light.
A feeding set, such as the kit 20 shown in FIG. 15 , is conveniently provided in packaged form ready for use in feeding a liquid enteral nutritional product. The kit includes a controlled release dosage form unit 32, a drip chamber 27 or other formulation chamber, and liquid communication means 28 consisting mainly of a length of flexible tubing attached at one end to the outlet of the drip chamber 27 and at the other end to a fitting 30 for coupling attachment to a feeding tube. The fitting 30 is shown with a cap 55 tele scoped for purposes of illustration. The cap is simply for protection of the fitting 30 until the feeding set is used. The controlled release dosage form unit 32 has already been placed in the drip chamber 27 and contains one or more beneficial ingredients as defined hereinabove for modifica tion of a liquid enteral nutritional product during feeding thereof, and additionally a marker dye, if desired. The kit may also be provided with a plurality of controlled release dosage form units 32 within the drip chamber 27 if a single dosage form unit does not contain each type of beneficial ingredient desired for modification of the nutritional product or if it is desired to add a marker dye and it is not present in the controlled release dosage form units for the beneficial ingredients selected.
A similar kit. 20c, as shown in FIG. 10 , includes the controlled release dosage form unit 32 which has not been placed in the drip chamber 27 before shipping the kit, but accompanies the drip chamber as part of the kit. Other kits are prepared with various numbers and varieties of con trolled release dosage form units containing various benefi cial agent and marker dye combinations and beneficial agents not in controlled release form, to accompany the feeding sets.
In a preferred embodiment of the apparatus of the inven tion of the type illustrated in FIG. 2 , a controlled release Blue #1 dye and is coated with a layer of the same blue dye admixed with about 3 percent by weight in total of polyvinylpyrrolidone having an average molecular weight in the range of about 35,000 to 44,500. The feeding kit is connected to a hanging supply container of a liquid enteral nutritional product having a viscosity of about 40 cps., such as PULMOCARE(R), a product of the Ross Products Division of Abbott Laborato ries, Columbus, Ohio, and a steady flow of the nutritional productis commenced. The dye coating provides immediate visible color within the drip chamber within2 seconds and the controlled release dosage form unit provides the blue dye in a concentration of at least 0.075 mg/ml for a period of over 1,440 minutes during the flow of about 3,000 ml of the liquid enteral nutritional product. The dosage form unit also provides glutamine at a concentration of at least 1.25 mg/ml during the flow of the liquid enteral nutritional product, commencing after about 1 ml of flow.
We claim:
1. A method of modifying a liquid enteral nutritional product during the flow thereof from a supply container containing such liquid enteral nutritional product to a feed ing tube leading into the gastrointestinal tract of a patient, comprising the steps of: .
(a) providing an apparatus comprising: a formulation chamber having an inlet and an outlet and the inlet being connectable to a supply container of the liquid enteral nutritional product so as to receive said product therefrom; at least one beneficial agent in at least one controlled release dosage form unit and the formulation cham ber comprising the at least one controlled release dosage form unit disposed therein so as to be wetted by or immersed in said liquid enteral nutritional product traversing therethrough, each beneficial agent being selected from the group consisting of nutrients, medicaments, probiotics and diagnostic agents that are each dispersible in said liquid enteral nutritional product; and fluid communication means capable of operatively con necting the outlet of the formulation chamber to a feeding tube which feeds said liquid enteral nutri tional product into the gastrointestinal tract of a patient, (b) providing a supply container containing said liquid enteral nutritional product having a viscosity in the range of about 5 to about 300 cps.;
(c) placing the apparatus in communicative series in the fluid flow between the supply container and said feed ing tube; and, (d) flowing the liquid enteral nutritional product through the apparatus and into said feeding tube throughout the feeding of a given quantity of the liquid enteral nutri tional product. 2. The method of claim 1 in which each beneficial agent provided in the formulation chamber employed is selected from the group consisting of nutrients, medicaments, pro biotics and diagnostic agents, and chemically and physi ologically compatible combinations thereof, and, any of the foregoing beneficial agents or chemically and physiologi cally compatible combinations thereof together with a physi ologically acceptable marker dye or mixture of dyes, each beneficial agent and marker dye disposed in the formulation chamber being dispersible in the medium of the liquid enteral nutritional product. 5,531,734 21 3. The method of claim 1 in which there is provided additionally in the formulation chamber at least one benefi cial agent not in controlled release dosage form, such beneficial agent being the same or different than any ben eficial agent present in controlled release dosage form.
4. The method of claim 2 in which there is provided additionally in the formulation chamber at least one benefi cial agent not in controlled release dosage form, such beneficial agent being the same or different than any ben eficial agent present in controlled release dosage form.
5. The method of any one of claims 2, 3 or 4 in which at least one controlled release dosage form unit provided in the formulation chamber employed is coated with a physiologi cally acceptable marker dye that is soluble in the medium of the liquid enteral nutritional product. 6. The method of any one of claims 1 through 4 in which there is provided in the formulation chamber employed a marker dye or mixture of dyes in a controlled release dosage form containing only the dye or mixture of dyes.
7. The method of either claim 1 or claim 2 in which the apparatus provided includes at least one additional formu lation chamber having therein at least one controlled release dosage formunit containing the same or different at least one beneficial agent.
8. The method of claim 1 in which the controlled release dosage form unit provided in the formulation chamber is an osmotically driven device.
9. The method of claim 8 in which the osmotically driven device provided in the formulation chamber comprises: an outer capsule formed by an exterior wall made up, at least in part, by a semipermeable composition that maintains its integrity in the presence of an aqueous O 15 25 22 fluid, the exterior wall surrounding a hydro-activated layer comprising a hydro-activated swellable compo sition or a hydro-activated composition that occupies space at a controlled rate, and an inner capsule sur rounded by the hydro-activated layer, the inner capsule containing at least a useful amount of the at least one soluble or dispersible beneficial agent in liquid formu lation form and the wall of the inner capsule being substantially non-permeable to the liquid enteral nutri tional product, and alumen, the lumen extending from the inner capsule to the exterior of the outer capsule, the inner capsule communicating with the lumen. 11. The method of any one of claims 1, 2, 3, 4, 8 or 9 in which the liquid enteral nutritional product has a viscosity in the range of from about 5 cps. to about 150 cps.
12. The method of claim 3 in which there is provided in the formulation chamber employed a marker dye or mixture of marker dyes in a controlled release dosage form.
13. The method of claim 8 in which there is provided in the formulation chamber employed a marker dye or mixture of marker dyes in a controlled release dosage form. 
